MiNK Therapeutics (INKT) to Release Earnings on Thursday

Key Points

• MiNK Therapeutics is expected to announce its Q2 2025 earnings results on Thursday, August 14th, with analysts projecting an earnings loss of ($0.45) per share.
• The company's stock price has decreased by 10.1%, opening at $13.06, after previously reaching a twelve month high of $76.00.
• Recent ratings changes include William Blair downgrading MiNK Therapeutics from "outperform" to "market perform," while B. Riley upgraded the stock to a "strong-buy" rating.

MiNK Therapeutics (NASDAQ:INKT - Get Free Report) is projected to post its Q2 2025 quarterly earnings results before the market opens on Thursday, August 14th. Analysts expect the company to announce earnings of ($0.45) per share for the quarter.

MiNK Therapeutics (NASDAQ:INKT - Get Free Report) last released its quarterly earnings results on Thursday, May 15th. The company reported ($0.70) earnings per share for the quarter, missing analysts' consensus estimates of ($0.61) by ($0.09). On average, analysts expect MiNK Therapeutics to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

MiNK Therapeutics Stock Down 4.7%

Shares of NASDAQ:INKT traded down $0.60 on Friday, reaching $12.06. The company had a trading volume of 175,191 shares, compared to its average volume of 422,964. The stock has a market capitalization of $48.07 million, a P/E ratio of -4.79 and a beta of 0.33. The stock has a 50-day moving average price of $13.05 and a 200 day moving average price of $9.97. MiNK Therapeutics has a twelve month low of $4.56 and a twelve month high of $76.00.

Wall Street Analyst Weigh In

INKT has been the topic of several analyst reports. B. Riley upgraded MiNK Therapeutics to a "strong-buy" rating in a report on Friday, July 18th. William Blair downgraded MiNK Therapeutics from an "outperform" rating to a "market perform" rating in a research report on Friday, July 11th. Finally, HC Wainwright downgraded MiNK Therapeutics from a "buy" rating to a "neutral" rating and set a $35.00 price target on the stock. in a research report on Tuesday, July 15th.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.